14 3 3 Proteins (Csf) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The 14-3-3 protein family is a group of conserved regulatory molecules expressed in all eukaryotic cells. In the context of neurodegenerative diseases, 14-3-3 proteins in cerebrospinal fluid (CSF) serve as important biomarkers for prion diseases and other conditions involving rapid neuronal damage.
| Property | Value |
|---|---|
| Category | CSF Biomarker |
| Target | 14-3-3 Proteins (β, ε, γ, η, σ, θ, ζ isoforms) |
| Sample Type | Cerebrospinal Fluid |
| Diseases | Creutzfeldt-Jakob Disease, Rapidly Progressive Dementia, ALS |
| Sensitivity | 80-95% for CJD |
| Specificity | 85-95% for CJD vs. other dementias |
The 14-3-3 family consists of seven isoforms (β, ε, γ, η, σ, θ, ζ) that function as adapter proteins involved in signal transduction, cell cycle regulation, and apoptosis. These proteins are abundant in neuronal tissue and are released into CSF following neuronal injury or death.
The detection of 14-3-3 proteins in CSF is a well-established diagnostic marker for sporadic CJD and other prion diseases. The test is included in the WHO diagnostic criteria for CJD.
14-3-3 CSF levels can help differentiate:
| Condition | 14-3-3 Status |
|---|---|
| Sporadic CJD | Typically Positive |
| Variant CJD | Usually Positive |
| Familial CJD | Usually Positive |
| FFI | Variable |
| Alzheimer's Disease | Usually Negative |
| Lewy Body Dementia | Usually Negative |
| Vascular Dementia | Usually Negative |
| Autoimmune Encephalitis | May be Positive |
Elevated 14-3-3 in CSF has been reported in:
| 14-3-3 Result | Interpretation |
|---|---|
| Strong Positive | High likelihood of prion disease |
| Weak Positive | Possible prion disease, consider repeat testing |
| Negative | Does not rule out prion disease |
Emerging research focuses on:
[1] Zerr I, et al. (2000). Assessment of 14-3-3 and tau proteins in CSF for differential diagnosis of prion disease. Lancet. 355(9206):721-722.
[2] Cuadrado-Corrales N, et al. (2010). The impact of 14-3-3 testing on the diagnosis of Creutzfeldt-Jakob disease. Clin Vaccine Immunol. 17(9):1416-1420.
[3] Choe LH, et al. (2012). 14-3-3 proteins in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 514(3):290-294.
[4] Collins SJ, et al. (2006). Diagnostic utility of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease. Neurology. 66(4):568-573.
[5] van Dellen E, et al. (2018). 14-3-3 proteins in cerebrospinal fluid as biomarkers for ALS. J Neurol Neurosurg Psychiatry. 89(9):961-967.
[6] Geschwind MD, et al. (2013). 14-3-3 protein in the CSF is not a useful biomarker for sporadic CJD. Ann Neurol. 74(2):297-298.
[7] Muayqil T, et al. (2012). A systematic review and meta-analysis of CSF 14-3-3 as a diagnostic marker for Creutzfeldt-Jakob disease. PLoS One. 7(6):e39352.
[8] Llorens F, et al. (2018). 14-3-3 protein isoforms and their implications in prion disease. Brain Pathol. 28(4):549-558.